Mutations in the endothelial nitric oxide synthase (eNOS) gene may be associated with abnormal nitric oxide (NO) production and cardiovascular diseases. In this study, we investigated the prevalence of two eNOS polymorphisms, the Glu298Asp variant on exon 7, and the 4a/b variable number of tandem repeats (VNTR) on intron 4, and their association with blood pressure (BP), NO production, salt sensitivity and cardiovascular risk factors in healthy Venezuelans. The prevalence of both polymorphisms in Venezuelans was comparable to that described for Caucasians, but significantly different from that known for African-Americans and Japanese. The 4a/b genotype was associated with reduced levels of NO metabolites (25% decrease), larger BP lowering in response to salt restriction (9.0 vs 4.8 mmHg, Po0.05), greater prevalence of salt sensitivity (39% in 4a/b and 27% in 4b/b; Po0.05) and with higher LDL-cholesterol levels. The Glu298T polymorphism did not affect NO production, nor it was associated with salt sensitivity. Glu298Asp polymorphism was positively associated with higher weight, triglycerides and LDL-cholesterol. Neither polymorphism was associated with changes in fasting or postload serum glucose, BP, obesity and albuminuria. In conclusion, the prevalence of eNOS polymorphisms is strongly determined by ethnic factors. The 4a/b gene polymorphism could be a genetic susceptibility factor for the BP response to salt intake and for the genetic control of NO production. The reduced NO production in subjects with the 4a/b genotype may be responsible for the increased sensitivity of their BP to salt.
Introduction
Salt sensitivity is characterized by an exaggerated blood pressure (BP) response to changes in salt intake. 1 Nitric oxide (NO) has been shown to play a role in intrarenal haemodynamics, sodium homeostasis and salt-sensitive hypertension. In animal models and in human subjects, salt sensitivity has been shown to be linked to impaired NO production. [2] [3] [4] [5] [6] Therefore, and because of the well-known role of NO on BP control, salt-sensitive hypertension and vascular function, mutations in the genes encoding for the NO synthesizing enzymes might be associated with salt sensitivity and cardiovascular diseases.
Endothelial NO synthase (eNOS) is one of the three isoforms of the NOS that can generate NO from its precursor L-arginine. Despite much evidence supporting the role for NO in salt sensitivity, prior to this work no studies had been conducted on the relationships between eNOS polymorphisms and salt sensitivity. In the present study, we evaluated the relationships between salt sensitivity and two eNOS gene polymorphisms; namely: (a) the 894 G/T substitutions in exon 7 of the eNOS gene, which results in a glutamate or aspartate, respectively, at codon 298 in the eNOS protein (Glu298Asp), and (b) the 27 bp variable number of tandem repeats (VNTR) polymorphism within intron 4 of the eNOS gene, with the variant a allele with four tandem repeats and the b allele with five tandem repeats. In addition, the association between eNOS polymorphisms and NO production, BP and cardiovascular risk factors was also evaluated. Finally, the unknown prevalence of eNOS polymorphisms in Venezuelans, a previously nonstudied ethnic group, was investigated.
Materials and methods

Study population
A total of 126 consecutive, otherwise healthy subjects, attending our Center for the Detection and Treatment of Silent Cardiovascular Risk Factors, were evaluated for eNOS polymorphism, salt sensitivity and cardiovascular risk factors. The exclusion criteria were: age greater than 70, a history of angina pectoris, myocardial infarction, congestive heart failure, valvular heart disease, cerebral infarction or haemorrhage, transient ischaemic attacks, arteriosclerosis obliterans, pulmonary disease; any patient with active disease, evidences of renal or hepatic dysfunction, urinary tract infection, active inflammatory disease states, severe hypertension, diabetes mellitus; treatment with organic nitrates, women on birth control pills and serum creatinine concentration greater than 2 mg/dl. Any medication was discontinued at least 4 weeks before the sodiumsensitivity protocol was started. The study was approved by the Institutional review Boards of NOVA Southeastern University and the University Hospital of the Central University of Venezuela. All participating subjects gave their informed consent.
Determination of salt sensitivity
Salt sensitivity testing was determined as previously described. 7 Briefly, subjects were placed on a high salt intake for 7 days, followed by a low-salt intake for an additional 7 days. On days 6 or 7 of both sodium diets, patients returned to the Center for the following procedures: systolic blood pressure (SBP), diastolic blood pressure (DBP), 24 h sodium and potassium excretion, 24 h nitrites and nitrates excretion, serum and urinary creatinine levels. The average of three BP determinations in supine position was used for determining salt sensitivity. Patients were classified as salt-sensitive, salt intermediate and salt resistant. If the difference in mean BP between high-and low-sodium weeks was equal to or more than 10 mmHg, the patient was deemed salt sensitive. Salt resistance was defined as increases of less than 3 mmHg, no change or decreases in mean BP. Subjects with BP increases greater than 3 but less than 10 mmHg were classified as of intermediate sensitivity to salt.
Genetic analysis-eNOS Glu298Asp polymorphism
DNA was extracted from blood anticoagulated with EDTA according to standard protocols. The G to T substitution polymorphism occurring at nucleotide position 894 of exon 7 in the eNOS gene, which results in the genetic variant of amino-acid residue 298, was evaluated. Genotyping was performed with polymerase chain reaction (PCR). Two allele-specific primers, FP 5 0 -TCC CTG AGG AGG GCA TGA GGC T-3 0 and RP 5 0 -TGA GGG TCA CAC AGG TTC CT-3 0 , were used in a single-tube reaction assay. The PCR was performed on a Perkin-Elmer Thermocycler in a 50 ml reaction mixture, containing 5 ml of genomic DNA solution, which contained 0.5 mmol/l of each primer, MgCl 2 -free Thermophillic DNA Polymerase Reaction buffer, 200 mmol/l of PCR Nucleotide Mix, 1.25 U Ampli-Taq DNA polymerase (Promega, Madison, WI, USA) and 1.5 mmol/l MgCl 2 . The conditions were initial denaturation for 5 min at 941C followed by 45 cycles of denaturation for 1 min at 941C, annealing for 1 min at 611C and extension for 1 min at 721C. The size of the PCR product was 457 bp and was used in the restriction enzyme assay. BanII (restriction enzyme), 10 U, were added to the PCR product and incubated at 371C for at least 20 h. The BanII digested the alleles containing G at nucleotide position 894 into two fragments of 137 and 320 bp, while leaving the DNA intact when T was present. The DNA was then resolved on a 2% agarose gel (Promega), stained with ethidium bromide and visualized under UV light. Subjects homozygous for the 298Glu or 298Asp alleles were identified as G/G or T/T, respectively. Subjects heterozygous for the polymorphism were identified as G/T.
Genetic Analysis-eNOS 4a/b polymorphism DNA was extracted from blood anticoagulated with EDTA according to standard protocols. The 27 bp VNTR polymorphism within intron 4 of the eNOS gene, with the variant a allele with four tandem repeats and the b allele with five tandem repeats, were quantified. Genotyping was performed with PCR. Two allele-specific primers, FP 5 0 -AGG CCC TAT GGT AGT GCC TTT-3 0 and RP 5 0 -TCT CTT AGT GCT GTG GTC AC-3 0 , were used in a single-tube reaction assay. The PCR was performed in a 30 ml reaction mixture, containing 5 ml of genomic DNA solution, which contained 0.25 mmol/l of each primer, MgCl 2 -free Thermophillic DNA Polymerase Reaction buffer, 200 mmol/l of PCR Nucleotide Mix, 1.25 U Ampli-Taq DNA polymerase and 1.5 mmol/l MgCl 2 . The conditions were initial denaturation at 951C for 5 min, followed by 35 cycles of denaturation for 50 s at 951C, annealing for 1 min at 471C and extension for 1 min at 721C. The size of the PCR products were 393 bp for the DNA containing the a allele and 420 bp for the DNA containing the b allele, which were resolved on a 3% agarose gel. After staining with ethidium bromide, PCR products were visualized under UV light. Subjects homozygous for the a and b alleles were identified as 4a/a and 4b/b, respectively, while heterozygous subjects were identified as 4a/b.
Determination of nitrites and nitrates in urine samples
Nitrites plus nitrates were quantified employing a modification of a commercially available NO assay kit (Oxford Biomedical research Inc., Oxford, MI, USA). 5 Urine samples (24 h) were collected at the end of the high-and low-sodium diets (10 days restriction from nitrate and nitrite containing foods). Nitrates present in the urine supernatant were reduced 1:1 to nitrites by incubation with metallic cadmium beads for 24 h. The total nitrite concentration was then estimated by the Griess reaction, using a multiwell microplate for reading of sample absorbance at 540 nm. This value represents the total amount of urine NO end products (nitrite þ nitrate). Urine samples were processed in duplicates.
Statistics and data analysis
Categorical variables were compared by means of the w 2 test. Continuous variables were compared by the Student's t-test for independent samples and paired t-test for paired samples or by a one-way ANOVA followed by a Duncan's test. Genetic equilibrium was confirmed by the Hardy-Weinberg criterion and was analysed by the w 2 test. Results are shown as mean values7s.e.m.; differences were considered significant at values of Po0.05. The assumption used for power calculation required a sample size of 50 subjects per group, which we have used (wild vs mutant) to provide an 80% power to detect a 30% reduction in the urinary excretion of NO metabolites with a 5% type I error rate for a onesided test.
Results
eNOS Glu 298Asp polymorphism
We found that 42% of subjects screened were G/T, 6.6% were homozygous to the mutation (T/T), and 51.4% carried the wild-type genotype (G/G) ( Table 1 ). The sample examined was in the HardyWeinberg equilibrium. Subjects with the T allele (G/ T þ T/T) had higher levels of LDL-cholesterol (P ¼ 0.01) and of triglycerides, and higher SBP than those carrying the wild-type gene (P ¼ 0.03) ( Table 1) . No significant differences were observed for the age, SBP, DBP, fasting serum glucose, HDL-cholesterol and urinary albumin excretion levels between both groups (Table 1) .
No differences in the BP response to changes in salt intake were observed in G/G and G/T subjects ( Figure 1 , Table 2 ). In addition, a similar percentage of salt sensitivity was found in the G/G and G/T groups (Table 2) . Changes in salt intake during the salt sensitivity testing were reflected by changes in urinary excretion of sodium (Table 3) . No significant differences in sodium excretion were observed between the groups of subjects when placed on high-or low-sodium diets. Similarly, no differences The urinary excretion of NO metabolites was quantified during customary, high and low levels of salt intake. There were no significant differences in the urinary excretion of NO metabolites between the G/G and the G/T groups (Figure 2 ). At customary sodium intake (B130 mEq/day), the urinary excretion of NO metabolites averaged 9787103 mmol/day in the G/G group and 9387108 mmol/day in the subjects with the T allele (G/T þ T/T). Under conditions of high salt intake and of salt restriction, the urinary excretion of NO metabolites averaged 781797 and 817780 mmol/day, respectively, in the G/G group, and 8817110 and 8807109 mmol/ day, respectively, in the G/T þ T/T group (P40.1).
eNOS intron 4 polymorphism
The frequency of the 4a/b VNTR polymorphism (4 or 5 repeats of 27 bp, respectively) in intron 4 of the eNOS gene was evaluated (Table 4) . We found that 65.1% of the subjects screened were 4b/b, 34.1% were 4a/b and only one subject (0.8%) was found 4a/a. The sample examined was in Hardy-Weinberg equilibrium. Higher levels of LDL-cholesterol were found in the 4a/b group than in the 4b/b group of individuals (P ¼ 0.01) ( Table 4) . No significant differences were observed in the age, SBP, DBP, fasting serum glucose, glucose levels during an oral tolerance test, HDL-cholesterol, triglycerides and urinary albumin excretion levels of both groups.
The BP response during the salt sensitivity testing was quantified. Shifting from a high-to a low-salt diet produced greater reductions in SBP in subjects Figure 1 , Table 5 ). In addition, more subjects were found to be salt sensitive in the 4a/b (39%) than in the 4b/b group (27%) (Po0.05). There were no significant differences in the amounts of sodium excreted by 4b/b and 4a/b subjects when either on high-or low-sodium diets (Table 6) . Similarly, no differences in the urinary excretion of potassium were observed between both groups (data not shown).
The daily urinary excretion of NO metabolites, expressed either as mmol/24 h or corrected for urinary creatinine (mmol/mg creatinine) (not shown), was significantly lower in the 4a/b group than in the 4b/b group (Po0.01) (Figure 2) . The reduced level of NO metabolite excretion observed in the 4a/b group was observed at three levels of salt intake, customary intake (around 13073 mEq/day), high salt intake (around 31076 mEq/day), and under salt restriction (around 3974 mEq/day) ( Figure 2 ).
Discussion
Three major genetic polymorphisms of the eNOS gene have been reported as susceptibility genes in a number of cardiovascular diseases ( Table 7) . Two of three polymorphims, the missense Glu298Asp variant and the VNTRs on intron 4, were investigated, because of their reported stronger associations with hypertension and cardiovascular diseases (Table 7) .
Ethnicity and eNOS polymorphisms
In addition to disease states, the prevalence of a specific genetic polymorphism is determined by ethnicity. The prevalence of eNOS polymorphism has been established for Caucasians, African-American and Japanese populations. However, such information is not available for Hispanics.
The Glu298Asp is less common in Japanese (5-10.2%) and African-Americans (10.5-16%), than in Caucasians (30-37%). 9, 12, 13, 23, 26, 34, 35 The frequency of the T allele in Venezuelans was comparable to that described for Caucasians, since the T allele was found in 30% of the Venezuelan subjects studied (present study).
The frequency of a allele for the VNTRs of intron 4 was also determined by ethnicity. The a allele was found more frequently in African-Americans (27-31%) than in Caucasians (16-18%) or Japanese (10-13%). 9, 26, [34] [35] [36] [37] Once again the frequency of a allele in Venezuelan subjects most closely compared to that of the Caucasians, since it was found in 18% of the Venezuelan subjects studied.
These findings further support the important role that ethnicity plays in determining the prevalence of genetic polymorphisms. The fact that the prevalence of two eNOS polymorphisms compares best with that of Caucasians is in support of the major European ancestry of the Venezuelan population studied.
eNOS polymorphisms, NO production and salt sensitivity Salt sensitivity is characterized by a substantial increase in BP following a high intake of salt. 38 The exact cause of salt sensitivity remains unknown. Both genetic and environmental factors interact to determine the BP response to changes in salt intake. 1, [38] [39] [40] Experimental evidence indicates that NO plays a key role in endothelial health and salt sensitivity. 41 In genetic models of salt sensitivity and in human subjects, salt sensitivity appears linked to impaired NO production, [2] [3] [4] [5] [6] an effect reversed by administration of the NO precursor, L-arginine. 42, 43 Despite numerous evidences supporting the role for NO in salt sensitivity, prior to this work no studies had been conducted on the relationships between eNOS polymorphisms and salt sensitivity.
In our study, we observed that the presence of the 4a/b polymorphisms was associated with salt sensitivity and with a reduction in the excretion of NO metabolites. Decreases in plasma NO metabolites have also been reported in healthy Japanese carrying 37 Owing to the existing relationship between reduced NO levels and salt sensitivity (see above), we propose that the reduced production of NO observed in subjects harbouring the 4a/b genotype could be responsible for the greater sensitivity of their BP to dietary salt. In addition to salt sensitivity, the 4a/b polymorphism has been shown to determine the efficacy of nevibolol, a betablocker that in addition increases the production of NO. [44] [45] [46] [47] Nebivolol is known to increase NO levels 46 possibly by inhibiting NO oxidation. 47 Nebivolol improved left ventricular hypertrophy and endothelial dysfunction in subjects carrying the b/b eNOS genotype, but failed to do so in those with the 4a/b genotype. 45 The diminished production of NO reported in subjects with the 4a/b mutation may prevent the beneficial effects of nebivolol. These results indicate that subjects carrying the 4a/b genotype may be at a higher risk of developing vascular dysfunction, salt sensitivity and poorer response to drugs that act by increasing NO availability.
eNOS polymorphisms, cardiovascular disease and risk factors
The missense Glu298Asp variant has been correlated with increased incidence of coronary spasm, 31 coronary heart disease, 22 myocardial infarction, 12 essential hypertension, 9,11 left ventricular hypertrophy, carotid atherosclerosis and cerebral infarction. 48 Whereas in other studies, no association between 298Asp with coronary artery disease, [22] [23] [24] [25] essential hypertension, [17] [18] [19] [20] [21] left ventricular hypertrophy and carotid atherosclerosis 17, 35 and cerebrovascular disease 29, 49 was observed.
In order to provide some light to these controversial results, we evaluated the possible existence of an association between the two more important eNOS polymorphisms and early cardiovascular risk factors. We observed that the 298Asp allele was not associated with BP, albuminuria or with fasting and postload glucose levels. However, as previously reported for Anglo-Celtic 17 and African-Americans, 26 in Venezuelans, the Glu298Asp polymorphism was found associated with modest increases in triglyceride and LDL-cholesterol (present study). It thus appears that irrespective of ethnicity, the presence of the Glu298Asp polymorphism carries an increased prevalence of cardiovascular risk factors (higher BMI, LDL-cholesterol and triglycerides). However, the increases were modest, and for the 298Asp carrying two rather than one allele did not increase the lipid abnormalities.
Polymorphisms of the VNTR on intron 4 of the eNOS gene have been associated with hypertension. [26] [27] [28] [29] However, such an association was not found in another studies. 10, 17 In our work, no association was found between the a allele and the baseline BP. However, tracking of the 4a allele with lower HDL-and higher LDL-cholesterol was reported in Anglo-Celtics 17 and with higher LDLcholesterol in hypertensive African-Americans. 26 In our study, in Venezuelans, the 4a allele was associated with increased LDL levels. It thus appears that the presence of the 4a/b polymorphism carries an increased prevalence of elevated LDLcholesterol.
In summary, the prevalence of the Glu298Asp and of the 4a/b eNOS polymorphism in Venezuelans is comparable to that reported for Caucasians. The 4a/b genotype was found associated with reduced NO production, increased salt sensitivity and increased Miyamoto et al; 9 Shoji et al; 10 Yasujima et al 11 Benjafield and Morris; 17 Karnoven et al; 18 Kato et al; 19 Lustberg et al; 20 Tsujita et al 21 Li et al; 26 Pulkkinen et al;
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eNOS polymorphisms and salt sensitivity IS Hoffmann et al levels of LDL-cholesterol. These observations suggest that the eNOS gene locus may be responsible for variations in the genetic control of plasma and urinary levels of NO metabolites, which in turn may favour a state of salt sensitivity. The 298Asp was found associated with higher triglyceride and LDLcholesterol levels. The role of these polymorphisms in the development and progression of atherosclerotic vascular disease needs further work.
